Wang L S, Chow K C, Li W Y, Liu C C, Wu Y C, Huang M H
Department of Surgery, Veterans General Hospital in Taipei and National Yang-Ming University, Taiwan, Republic of China.
Clin Cancer Res. 2000 Apr;6(4):1445-51.
Although the serum level of soluble interleukin-2 receptor alpha (sIL-2Ralpha) has been shown to correlate with progression and prognosis of several cancers, data to support its clinical significance to esophageal squamous cell carcinoma (ESCC) are limited. This study was conducted to assess the prognostic value and source of sIL-2Ralpha in patients with ESCC. From January 1986 to June 1997, 125 patients with histopathologically confirmed ESCC were enrolled for study. Ninety-three patients underwent en bloc esophagectomy, and 32 patients with unresectable tumor underwent palliative surgery. Four (4.3%; 4 of 93) patients died of surgical complications. Serum levels of sIL-2Ralpha were measured by ELISA. Expression of IL-2Ralpha, IL-2Rbeta, and IL-2Rgamma in the pathological section was determined, respectively, by immunohistochemistry (IHC) and in situ hybridization (ISH). Compared with the healthy control group (1020 +/-476 pg/ml, n = 103), ESCC patients tended to have significantly higher serum sIL-2Ralpha concentrations (1424 +/- 798 pg/ml, n = 121). The sIL-2Ralpha level was correlated with age, Tumor-Node-Metastasis classification, tumor stage, reading score of the IHC staining, and survival but not with the pathological grade or lymphovascular invasion. Prognosis was worse for patients with high sIL-2Ralpha levels (> or =1500 pg/ml) than for those with low serum sIL-2Ralpha levels (< 1500 pg/ml; P = 0.0209). It can be used as an independent prognostic factor of ESCC. In the pathological sections, expression of IL-2Ralpha, IL-2Rbeta, and IL-2Rgamma was detected in 17 (18.1%), 83 (89.2%), and 83 (89.2%) cases, respectively, by IHC, and the message of IL-2Ralpha was identified in tumor cells by ISH in 30.1% (28 of 93) of the cases. Serum concentrations of sIL-2Ralpha are frequently elevated in ESCC patients and are correlated with disease progression and survival. These data indicate that, in addition to activated T cells, cancer cells could be an important source of sIL-2Ralpha in ESCC patients.
尽管可溶性白细胞介素-2受体α（sIL-2Rα）的血清水平已被证明与多种癌症的进展和预后相关，但支持其对食管鳞状细胞癌（ESCC）临床意义的数据有限。本研究旨在评估ESCC患者中sIL-2Rα的预后价值和来源。1986年1月至1997年6月，125例经组织病理学确诊的ESCC患者纳入研究。93例患者接受了食管癌整块切除术，32例无法切除肿瘤的患者接受了姑息手术。4例（4.3%；93例中的4例）患者死于手术并发症。采用酶联免疫吸附测定法（ELISA）检测血清sIL-2Rα水平。分别通过免疫组织化学（IHC）和原位杂交（ISH）检测病理切片中IL-2Rα、IL-2Rβ和IL-2Rγ的表达。与健康对照组（1020±476 pg/ml，n = 103）相比，ESCC患者的血清sIL-2Rα浓度往往显著更高（1424±798 pg/ml，n = 121）。sIL-2Rα水平与年龄、肿瘤-淋巴结-转移分类、肿瘤分期、IHC染色的阅片评分及生存相关，但与病理分级或脉管浸润无关。sIL-2Rα水平高（≥1500 pg/ml）的患者预后比血清sIL-2Rα水平低（<1500 pg/ml）的患者更差（P = 0.0209）。它可作为ESCC的独立预后因素。在病理切片中，通过IHC分别在17例（18.1%）、83例（89.2%）和83例（89.2%）病例中检测到IL-2Rα、IL-2Rβ和IL-2Rγ的表达，通过ISH在30.1%（93例中的28例）病例的肿瘤细胞中检测到IL-2Rα的信息。ESCC患者血清sIL-2Rα浓度经常升高，并与疾病进展和生存相关。这些数据表明，除了活化的T细胞外，癌细胞可能是ESCC患者sIL-2Rα的重要来源。
